1. Home
  2. PRLB vs TBPH Comparison

PRLB vs TBPH Comparison

Compare PRLB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Proto Labs Inc.

PRLB

Proto Labs Inc.

HOLD

Current Price

$53.65

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$20.22

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRLB
TBPH
Founded
1999
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
993.7M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
PRLB
TBPH
Price
$53.65
$20.22
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$53.00
$27.80
AVG Volume (30 Days)
124.7K
370.5K
Earning Date
02-06-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.61
0.58
Revenue
$518,384,000.00
$80,327,000.00
Revenue This Year
$7.07
$70.78
Revenue Next Year
$4.87
N/A
P/E Ratio
$90.17
$35.74
Revenue Growth
2.82
27.12
52 Week Low
$29.59
$7.90
52 Week High
$56.60
$21.03

Technical Indicators

Market Signals
Indicator
PRLB
TBPH
Relative Strength Index (RSI) 51.19 60.45
Support Level $52.95 $19.53
Resistance Level $56.60 $21.03
Average True Range (ATR) 1.64 0.83
MACD -0.03 0.07
Stochastic Oscillator 51.68 76.45

Price Performance

Historical Comparison
PRLB
TBPH

About PRLB Proto Labs Inc.

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: